



HAL
open science

High-Level Biosynthesis of the Anteiso-C17 Isoform of the Antibiotic Mycosubtilin in *Bacillus subtilis* and Characterization of Its Candidacidal Activity

Patrick Fickers, Jean-Sebastien Guez, Christian Damblon, Valérie Leclère, Max Béchet, Philippe Jacques, Bernard Joris

► **To cite this version:**

Patrick Fickers, Jean-Sebastien Guez, Christian Damblon, Valérie Leclère, Max Béchet, et al.. High-Level Biosynthesis of the Anteiso-C17 Isoform of the Antibiotic Mycosubtilin in *Bacillus subtilis* and Characterization of Its Candidacidal Activity. *Applied and Environmental Microbiology*, 2009, 75 (13), pp.4636-4640. 10.1128/AEM.00548-09 . hal-02941974

HAL Id: hal-02941974

<https://hal.science/hal-02941974>

Submitted on 17 Sep 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **High level biosynthesis of the mycosubtilin antibiotic anteiso-C17 isoform in *Bacillus***
2 ***subtilis* and characterisation of its candidacidal activity.**

3

4

5 Patrick Fickers^{1†*}, Jean-Sébastien Guez^{2†}, Christian Damblon³, Valérie Leclère², Max
6 Béchet², Philippe Jacques² and Bernard Joris¹

7

8

9 **Authors' affiliation :**

10 ¹ Centre d'Ingénierie des Protéines, Université de Liège, Institut de Chimie, Bat B6, B-4000
11 Liège, Belgium.

12 ² Laboratoire de Procédés Biologiques, Génie Enzymatique et Microbien (ProBioGEM,
13 UPRES EA 1026), Polytech'Lille, Université des Sciences et Technologies de Lille, F-59655
14 Villeneuve d'Ascq Cedex, France

15 ³ Chimie Biologique Structurale, Université de Liège, Institut de Chimie, Bat B6, B-4000
16 Liège, Belgium.

17

18 **Footnote :** † Both authors contributed equally to this article

19

20 ***Corresponding author :**

21 Mailing address : Centre d'Ingénierie des Protéines, Laboratoire de Physiologie et Génétique
22 Bactérienne, Université de Liège, Institut de Chimie, Bat B6, B-4000 Liège, Belgium

23 Phone : + 32 4 366 3348

24 Fax : + 32 4 366 3364

25 E-mail : pfickers@ulg.ac.be

26 **Abstract**

27 High-level production (880 mg l⁻¹) and isolation of the anteiso-C17 isoform of the lipopeptide
28 mycosubtilin, produced by a genetically engineered *B. subtilis* strain is reported. Antifungal
29 activity of this isoform, as determined via culture, fluorometric and cell leakage assays,
30 suggest its potential therapeutic use as antifungal agent, in particular on *Candida* sp.

31

32

33 **Short-form paper**

34 The soil bacterium *Bacillus subtilis* ATCC 6633 synthesises the lipopeptides
35 mycosubtilin and surfactin by so-called non-ribosomal peptide synthetase. Mycosubtilin
36 belongs to the iturin family and is composed of seven α -amino acids linked to a unique C16 or
37 C17 β -amino fatty acid with a linear or branched (iso or anteiso) acyl chain (15). This
38 amphiphilic structure confers interesting biological properties to this secondary metabolite,
39 particularly antifungal activity, which increases with the number of carbon atoms of the acyl
40 chain (10). However, studies and applications of mycosubtilin are compromised by limited
41 production by the native producer, co-synthesis of surfactin, and the existence of different
42 mycosubtilin homologues and isoforms. In this work, utilisation of specific precursors
43 together with appropriate culture conditions for a genetically engineered strain led to the
44 synthesis of a large amount of the most biologically active mycosubtilin homologue.
45 Structural characterisations by mass spectrometry and NMR spectroscopy demonstrated that
46 this homologue corresponds to the anteiso-C17 isoform. Its antifungal activity on pathogenic
47 *Candida* sp. was examined by MIC determination, fluorescence spectroscopy and leakage
48 experiments.

49 Overproduction of mycosubtilin in *B. subtilis* ATCC 6633 was obtained by
50 replacement of the native promoter of the *myc* operon which encodes mycosubtilin synthetase
51 by the strong and tightly regulated *xylA* promoter from the *B. megaterium* xylose isomerase
52 (16). To this end, a repressor-promoter *xylR-pxylA* fragment was PCR-amplified from pAXO1
53 (9) with *pfu* DNA polymerase (Promega) and primers R100/R101 before being cloned at the
54 *HincII* site of pBG103 to yield pBG113 (Tables 1 and 2). Then, a spectinomycin resistance
55 cassette was rescued from pRFB122 by *PstI/EagI* digestion and inserted into pBG113 at the
56 corresponding site to yield pBG113s (Table 1). This latter construct was used to transform *B.*
57 *subtilis* ATCC 6633 as previously described (8) and transformants were selected on Luria-

58 Bertani plates supplemented with spectinomycin (100 µg/ml). Correct integration in the
59 resulting RFB107 strain was verified by analytical PCR using primers R102/R103 (Table 2).
60 In a second step, the *srf* operon encoding surfactin synthetase was disrupted in RFB107 to
61 render the strain unable to synthesise surfactin. The knockout was targeted downstream of the
62 *comS* regulator involved in competence mechanisms which lies nested and out of frame
63 within the *srf* operon (5, 6). The disruption cassette was obtained by a ligation-mediated PCR
64 method (12) as follows: fragments of *srfAB* and *srfAD* ORFs were PCR-amplified (primers
65 R106/R107 and R108/R109, respectively) from *B. subtilis* ATCC 6633 genomic DNA
66 (obtained with the Wizard Genomic DNA purification kit, Promega) while the erythromycin
67 resistance cassette (ERY) of pDML1567 was amplified with primer R110/R111. PCR
68 fragments (200 ng) were *Sfi*I-digested, purified with the GFX purification kit (GE Healthcare)
69 and ligated with T4 DNA ligase (Promega) before being used as a template for PCR
70 amplification using primer R106/R109. The resulting *srfAB*-ERY-*srfAD* cassette was then
71 used to transform *B. subtilis* RFB107 and transformants were selected on LB erythromycin
72 plates (1 µg/ml). Integration by double crossing event in the resulting strain RFB112 was
73 verified by analytical PCR using primer R104/R105 (Table I) and by LC-ESI-MS analysis of
74 the purified culture supernatant as described elsewhere (14).

75 For mycosubtilin production, strain RFB112 was cultured at 25°C for 48 h in a
76 medium containing yeast extract 1 g l⁻¹, sucrose 15 mM, xylose 75 mM, isoleucine 15 mM,
77 K₂HPO₄ 10 mM, MgSO₄ 4 mM and KCl 6 mM. Mycosubtilin concentration in the culture
78 broth, determined by reverse-phase HPLC on a C18 X-Terra column (4.6 x 15 mm, 3.5 µmX,
79 Waters) (8), was 880 mg l⁻¹. This represents a 50-fold increased production yield compared to
80 the native strain for a culture time reduced by up to 40% (8). For mycosubtilin purification,
81 the culture supernatant was loaded onto a 50 ml C18 ODS matrix (Macherey-Nagel)
82 equilibrated with 10 bed volumes of MilliQ water. The matrix was subsequently washed with

83 MilliQ water and with a mixture of MilliQ water:methanol (1:1 v/v) (5 bed volumes each).
84 Crude mycosubtilin was then eluted with 3 bed volumes of methanol before being 10-fold
85 concentrated by rotary evaporation. Further purification was performed by reverse-phase
86 HPLC and the peak corresponding to the mycosubtilin was collected and vacuum-dried. The
87 purified molecule, analyzed by MALDI-TOF mass spectrometry as previously described (13),
88 showed signals at m/z 1107.5 and 1123.5 Da which are in accordance with the calculated
89 mass values of Na^+ and K^+ adducts of the C17 mycosubtilin homologue. Additional ions
90 corresponding to C16 homologues were not detected, suggesting that the latter were not
91 synthesized under these conditions (Fig. 1). Acyl chain isomery was further characterised
92 either by ^1H and ^1H - ^{13}C HSQC NMR spectroscopy (18) on a Bruker 500 MHz spectrometer at
93 25°C with a 10 mM solution of purified mycosubtilin in methanol- d_4 . In the high-field methyl
94 region, two signals were observed at (δ_{H} 0.89, δ_{C} 18.5) and (δ_{H} 0.93, δ_{C} 13), corresponding to
95 a doublet and a triplet with J values of 6.9 Hz and 7.4 Hz, respectively (Fig. 2 and not shown).
96 These signals with very low proton chemical shift (δ_{H} 0.89 and δ_{H} 0.93) correspond to
97 methyl groups of the long chain β -amino acid found in iturin lipopeptide (11). The proton
98 multiplicity (i.e. doublet and triplet) observed for this two methyl groups could only account
99 for the anteiso isomery of the heptadecanoic acyl chain of mycosubtilin.

100 The biological activity of the purified anteiso-C17 mycosubtilin was first characterised
101 by determining the susceptibility of an array of yeasts and molds. As shown in Table 3, a
102 strong antifungal activity was obtained for yeast strains whereas no significant growth
103 inhibition was observed for molds. Despite varying susceptibilities toward both yeast species
104 and specific isolates of the same species, the relatively low MIC values obtained, especially
105 for isolates resistant to conventional drugs (fluconazole and/or amphotericin B), point to the
106 powerful properties of this particular mycosubtilin isoform. The moderate effectiveness
107 against the sterol auxothrophic *C. glabrata* isolates could be explained by the presence of free

108 ergosterol in the culture medium which is known as a strong iturin antagonist (2). For iturin
109 A, a closely related iturinic lipopeptide to mycosubtilin, a membrane pore-forming mode of
110 action has been suggested for *Saccharomyces cerevisiae* spheroplast (3). Accordingly, the
111 antifungal activity of the purified mycosubtilin was further investigated by determining its
112 ability to induce cell membrane destabilisation by measuring the transmembrane electrical
113 potential ($\Delta\Psi$) with the fluorescent probe 3'-dipropylthia dicarbocyanine iodide [DiSC₃ (5)]
114 (7). As shown in Fig. 3, the significant fluorescence signal observed upon addition of 10 μ M
115 of mycosubtilin to a *C. albicans* reference strain ATCC 10231 cell suspension loaded with
116 fluorescent dye demonstrated the complete disruption of the $\Delta\Psi$ (as shown by the lack of an
117 additional fluorescence signal upon addition of the ionophore valinomycin). At the same time,
118 an extensive cell leakage of UV-absorbing molecules (i.e. protein and nucleic acids; for
119 details see ref. (17)) could be observed, suggesting the formation of transmembrane pores due
120 to the action of mycosubtilin (not shown).

121 Considering that the antifungal activity of iturinic lipopeptides increases with the length
122 of their fatty acid moiety and that mycosubtilin is considered as the most active iturin (10),
123 the aim of this study was to specifically overproduce a C17 mycosubtilin homologue. As this
124 lipopeptide is of great fundamental interest and shows great antibiotic potential, its study is
125 particularly worthwhile. The extent to which mycosubtilin overproduction occurs in the
126 engineered strain is greater than what has ever been observed to date (13). In combination
127 with low culture temperature, which also contributes to this high level of production (8),
128 addition of isoleucine made it possible to direct mycosubtilin synthesis toward the anteiso-
129 C17 isoform with high efficiency. This preliminary investigation on the antifungal properties
130 of this particular mycosubtilin isoform is very promising and must be pursued. We are
131 currently investigating the mechanism of antifungal activity in greater detail, especially on
132 *Candida* strains less susceptible to conventional antifungal drugs.

133

134

135 **Acknowledgments**

136 This work received financial support from the Université des Sciences et Technologie de
137 Lille, the Region Nord-Pas-de-Calais and the Fonds Européen pour le Développement. P.
138 Fickers is a post-doctoral researcher at the F.N.R.S. (National Fund for Scientific Research,
139 Belgium). We are grateful to Dr. Ongena (CWBI, Agricultural University of Gembloux,
140 Belgium) for LC-ESI-MS experiments, to Dr. De Tulio. (Chimie Pharmaceutique, University
141 of Liège, Belgium) for technical assistance with the 500 MHz NMR spectrometer and to Dr.
142 Hazen (Department of Pathology, University of Virginia Health System, Charlottesville,
143 USA) for providing the clinical isolates of *C. glabrata*.

144 .

145

146 **References**

- 147 1. **Bard, M., A. M. Sturm, C. A. Pierson, S. Brown, K. M. Rogers, S. Nabinger, J.**
148 **Eckstein, R. Barbuch, N. D. Lees, S. A. Howell, and K. C. Hazen.** 2005. Sterol
149 uptake in *Candida glabrata*: rescue of sterol auxotrophic strains. *Diagn. Microbiol.*
150 *Infect. Dis.* **52**:285-93.
- 151 2. **Besson, F., F. Peypoux, G. Michel, and L. Delcambe.** 1979. Antifungal activity
152 upon *Saccharomyces cerevisiae* of iturin A, mycosubtilin, bacillomycin L and of their
153 derivatives; inhibition of this antifungal activity by lipid antagonists. *J. Antibiot.*
154 **32**:828-33.
- 155 3. **Besson, F., F. Peypoux, M. J. Quentin, and G. Michel.** 1984. Action of antifungal
156 peptidolipids from *Bacillus subtilis* on the cell membrane of *Saccharomyces*
157 *cerevisiae*. *J. Antibiot.* **37**:172-177.
- 158 4. **Clinical and laboratory standards institute.** 2008. Reference method for broth
159 dilution antifungal susceptibility testing of yeast; approved standard. Third edition.
160 Clinical and laboratory standards institute press. CLSI document M27-A3.
- 161 5. **D'Souza, C., M. M. Nakano, D. L. Frisby, and P. Zuber.** 1995. Translation of the
162 open reading frame encoded by *comS*, a gene of the *srf* operon, is necessary for the
163 development of genetic competence, but not surfactin biosynthesis, in *Bacillus*
164 *subtilis*. *J. Bacteriol.* **177**:4144-4148.
- 165 6. **D'Souza, C., M. M. Nakano, and P. Zuber.** 1994. Identification of *comS*, a gene of
166 the *srfA* operon that regulates the establishment of genetic competence in *Bacillus*
167 *subtilis*. *Proc. Natl. Acad. Sci. U S A* **91**:9397-9401.
- 168 7. **Dortu, C., P. Fickers, C. Franz, D. Ndagano, M. Huch, W. Holzapfel, B. Joris,**
169 **and P. Thonart.** 2009. Characterisation of an antilisterial bacteriocin produced by






- 170 *Lactobacillus sakei* CWBI-B1365 isolated from raw poultry meat and determination
171 of factors controlling its production. Prob. Antimicrob. pept. In Press.
- 172 8. **Fickers, P., V. Leclere, J. S. Guez, M. Bechet, F. Coucheney, B. Joris, and P.**
173 **Jacques.** 2008. Temperature dependence of mycosubtilin homologue production in
174 *Bacillus subtilis* ATCC 6633. Res. Microbiol. **159**:449-457.
- 175 9. **Hartl, B., W. Wehrl, T. Wiegert, G. Homuth, and W. Schumann.** 2001.
176 Development of a new integration site within the *Bacillus subtilis* chromosome and
177 construction of compatible expression cassettes. J. Bacteriol. **183**:2696-2699.
- 178 10. **Hhid, C.** 1996. PhD thesis, Univesity of Liège, Liège, Belgium.
- 179 11. **Kajimura, Y., M. Sugiyama, and M. Kaneda.** 1995. Bacillopeptins, new cyclic
180 lipopeptide antibiotics from *Bacillus subtilis* FR-2. J. Antibiot. **48**:1095-1103.
- 181 12. **Kamper, J.** 2004. A PCR-based system for highly efficient generation of gene
182 replacement mutants in *Ustilago maydis*. Mol. Genet. Genomics **271**:103-110.
- 183 13. **Leclere, V., M. Bechet, A. Adam, J. S. Guez, B. Wathelet, M. Ongena, P.**
184 **Thonart, F. Gancel, M. Chollet-Imbert, and P. Jacques.** 2005. Mycosubtilin
185 overproduction by *Bacillus subtilis* BBG100 enhances the organism's antagonistic and
186 biocontrol activities. Appl. Environ. Microbiol. **71**:4577-4584.
- 187 14. **Nihorimbere, V., P. Fickers, P. Thonart, and M. Ongena.** 2009. Ecological fitness
188 of *Bacillus subtilis* BGS3 regarding production of the surfactin lipopeptide in the
189 rhizosphere. Environ Microbiol. Rep. **1**: 124-130
- 190 15. **Ongena, M., and P. Jacques.** 2008. *Bacillus* lipopeptides: versatile weapons for plant
191 disease biocontrol. Trends Microbiol. **16**:115-125.
- 192 16. **Rygun, T., A. Scheler, R. Allmansberger, and W. Hillen.** 1991. Molecular cloning,
193 structure, promoters and regulatory elements for transcription of the *Bacillus*
194 *megaterium* encoded regulon for xylose utilization. Arch. Microbiol. **155**:535-542.

- 195 17. **Thimon, L., F. Peypoux, J. Wallach, and G. Michel.** 1995. Effect of the lipopeptide
196 antibiotic, iturin A, on morphology and membrane ultrastructure of yeast cells. *FEMS*
197 *Microbiol. Lett.* **128**:101-106.
- 198 18. **Wilker, W., D. Leifritz, R. Kerrsebaum, and W. Bermel.** 1993. Gradient selection
199 in inverse heteronuclear correlation spectroscopy. *Magn. Reson. Chem.* **31**:287-292.
200
201

202

203

TABLE 1. Plasmids and *Bacillus* strains used in this study

Plasmids	Description or genotype	Source or reference
pBG103		(13)
pBG113		This work
pBG113s		This work
pRFP129		This work
pRFB122	pGEMTeasy carrying a spectinomycin resistance gene	Fickers, unpublished
PDML1567	pGEMTeasy carrying a erythromycin resistance gene	Fickers, unpublished
<i>B. subtilis</i>		
ATCC6633	Wild-type strain producing mycosubtilin and surfactin	Lab stock
		
RFB107	ATCC 6633 overproducing derivative, xylose inducible	This work
RFB112	RFB107 derivative surfactin non-producer	This work

204

TABLE 2. Synthetic primers used for PCR amplification

Name	Sequence (5'-3')	Restriction site
R100	GGGAGCTCGGATCCCATTTC	-
R101	CGATATCTCTGCAGTCGCGATG	-
R102	CCACTCCTTTGTTTATCCACCGAAC	-
R103	GACGTTCAAATAAGTGTGATTGGCC	-
R104	ACGGAGGGAGACGATTTGCA	-
R105	ACATTCGGTGAATAAGGAAGCA	-
R106	GTGAAAATCCGAGGCTACCGC	-
R107	GGGGGCCCCAGCGGCCATATAAGCCGCCAGCTGGCG	<i>Sfi</i> I
R108	CAGGGGCCAGTGGGCCGCAGGGCGAAACGCTAGATAGG	<i>Sfi</i> I
R109	GCTGTCACAAACGGAAGAAGTC	
R110	CATGGCCCACTGGGCCCTGCTTCCTAATGCAGGAGTCGC	<i>Sfi</i> I
R111	CCCCGGCCGCTGGGGCCCCCGGATCGCCTATTTGGC	<i>Sfi</i> I

206

207

TABLE 3 : *In vitro* susceptibility of different yeasts and molds toward purified anteiso-C17 mycosubtilin. Results are mean values of four independent experiments. Breakpoints for the determination of antibiotic resistance were determined according to the M27-A3 procedure (4). Experiments were performed in triplicate.

Strain	MIC ($\mu\text{g/ml}$)	Origin or Reference
<i>Sacharomyces cerevisiae</i>	4	Lab stock
<i>Yarrowia lipolytica</i> CBS6303	8	CBS
<i>Pichia pastoris</i>	32	Lab stock
<i>Candida albicans</i> ATCC10231 ^A	32	ATCC
<i>Candida albicans</i> IHEM3742	64	IHEM
<i>Candida. albicans</i> ^A	18	Lab stock
<i>Candida parapsilosis</i> IHEM9557	128	IHEM
<i>Candida tropicalis</i> IHEM6246	16	IHEM
<i>Candida tropicalis</i> ^{A, B, C}	16	Lab stock
<i>Candida guilliermondii</i> IHEM1067	128	IHEM
<i>Candida glabrata</i> IHEM6161	16	IHEM
<i>Candida glabrata</i> L999	2	(1)
<i>Candida glabrata</i> S53452 ^{A, C, D}	150	(1)
<i>Candida glabrata</i> H34736 ^{A, C, D}	150	(1)
<i>Candida glabrata</i> W16119 ^{A, C, D}	150	(1)
<i>Candida glabrata</i> ^{A, C}	16	Lab stock
<i>Cryptococcus neoformans</i> IHEM3969	8	IHEM
<i>Aspergillus parasiticus</i> IHEM4383	> 300	IHEM
<i>Aspergillus terreus</i> IHEM2499	> 300	IHEM
<i>Aspergillus fumigatus</i> IHEM3562	> 300	IHEM

IHEM : Biomedical fungi and yeasts collection (<http://bccm.belspo.be>); ATCC : American type culture collection (<http://www.lgcpromochem-atcc.com>), CBS : Centraalbureau voor Schimmelcultures, Fungal and Yeast Collection (<http://www.cbs.knaw.nl/databases/index.htm>)

^A resistant to fluconazole

^B resistant to amphotericin B

^C clinical isolate

^D auxothroph for sterol, culture medium was supplemented with ergosterol 20 $\mu\text{g/ml}$

211

212 **Figure legends**

213

214 **Figure 1** : Matrix-assisted laser desorption/ionization-time of flight spectra of lipopeptide
215 produced by *B. subtilis* RFB112 .

216

217 **Figure 2** : Detail of ^1H - ^{13}C HSQC spectra of lipopeptide produced by *B. subtilis* strain
218 RFB112. Spectra were acquired according to (18). The methyl signals are indicated by an
219 arrow.

220

221 **Figure 3** : Transmembrane electrical potential ($\Delta\Psi$) determination of a *C. albicans* ATCC
222 10231 suspension (0.5 McFarland). Fluorophore Disc(3)5 (1 μM , arrow 1), mycosubtilin (15
223 μM , arrow 2) and valinomycin (1 μM , arrow 3) were added to the cell suspension after 50,
224 600 and 1000 seconds, respectively. Displayed data are one representative result of three
225 independent experiments.


226

227 **Figure 1 : MALDI-TOF spectra of lipopeptide produced by *B. subtilis* strain RFB112**

228

229


230



231


232
233 **Figure 2 : Detail of ^1H - ^{13}C HSQC spectra of lipopeptide produced by *B. subtilis* strain RFB112**

234
235
236
237
238
239



240 **Figure 3 : Transmembrane electrical potential ($\Delta\Psi$) determination of a *C. albicans* ATCC 10231 suspension**

241



242

243

244

245

246

247

248

249